One of the most powerful evidentiary tools available to plaintiffs is the use of a company's own bad documents against it at trial. In this age of technology, bad documents are more likely to be accessible because of increased use of computers, e-mail, and the Internet. Under the Federal Food, Drug, and Cosmetic Act and its accompanying regulations, drug and medical device manufacturers submit product safety reports to the Federal Drug Administration. Adverse Drug Events (ADEs) should be excluded from evidence at trial because they lack reliability, they lack relevance, and they pose a significant danger of unfair prejudice, issue confusion, and waste of time. Despite their marginal relevance to the case, preventing the facts contained in bad company documents from becoming influential ...
GAITHERSBURG, Md., June 28, 2012 /PRNewswire-USNewswire/ -- Furthering its goal to increase the use of non-animal testing methods internationally, the Institute for In Vitro Sciences (IIVS) hosted a four -day workshop for eleven attendees from Russia. Through a combination of lectures and hands-on laboratory training, the delegates gained firsthand knowledge of how non-animal test methods can be used to assess the safety of cosmetic and personal care products. Scientists in Russia are interested in learning more about non- animal test methods. This course gave an extremely useful technical overview and also highlighted how the data from these methods can be incorporated into a product safety testing program," said Tatiana Puchkova, Chairman of the Board of Perfumery and Cosmetic Associ...
WASHINGTON, March 7, 2012 /PRNewswire/ -- The Cosmetic Ingredient Review (CIR), an independent panel of scientific and medical experts, reaffirmed this week at their public meeting that parabens, a family of preservatives used in cosmetics and personal care products, are safe. The cosmetic industry formally requested that CIR re-examine the safety of parabens as they are used in cosmetics, and we are gratified that the panel has done so and confirmed the safety of these ingredients," said Halyna Breslawec, chief scientist for the Personal Care Products Council (the Council). "The Council also appreciates that the Consumer Federation of America (CFA) and the U.S. Food and Drug Administration (FDA) supported the CIR decision," she said.
Pursuant to section 994(a), (o), and (p) of title 28, United States Code, the United States Sentencing Commission is considering promulgating certain amendments to the sentencing guidelines, policy statements, and commentary. This notice sets forth the proposed amendments and, for each proposed amendment, a synopsis of the issues addressed by that amendment. This notice also sets forth a number of issues for comment, some of which are set forth together with the proposed amendments; some of which are set forth independent of any proposed amendment; and one of which (regarding retroactive application of proposed amendments) is set forth in the SUPPLEMENTARY INFORMATION portion of this notice. The proposed amendments and issues for comment in this notice are as follows: (1) A proposed ame...
... offenses involving pre-retail medical products to implement the directive in the SAFE DOSES Act, ... 717 of the Food and Drug Administration Safety and Innovation Act, Public Law 112-144 (July 9, 20... Food, Drug, Biological Product, Device, Cosmetic, Agricultural Product, or Consumer Product) or App...
... the packaging security and help assure the safety of those products. Such a cosmetic product for ret...
...This patchwork is primarily a product of U.S. federalism, which allocates sovereign powe... and drugs (e.g., the Food, Drug, and Cosmetic Act), household goods (e.g., the Consumer Product Safety Act), and consumer financial products and services...
The Food and Drug Administration (FDA) is announcing the rates for biosimilar user fees for fiscal year (FY) 2013. The Federal Food, Drug, and Cosmetic Act (the FD&C Act), as amended by the Biosimilar User Fee Act of 2012 (BsUFA) (Title IV of the Food and Drug Administration Safety and Innovation Act, Public Law 112-144, which was signed by the President on July 9, 2012), authorizes FDA to assess and collect user fees for certain activities in connection with biosimilar biological product development, for certain applications and supplements for approval of biosimilar biological products, on establishments where approved biosimilar biological product products are made, and on biosimilar biological products after approval. BsUFA directs FDA to establish, before the beginning of each ...
... a similar legislative bill, the Cosmetics Safety Enhancement Act, H.R. 4262. And just last April, R... cosmetics companies to submit proposed products or components, other than color additives, for pre...
Oragenics, Inc. Michael Sullivan, 813-286-7900 x246
... third party review of its Cosmetic Product Safety Report. ProBiora3(R) is Oragenics' propriet...
ver las páginas en versión mobile | web
ver las páginas en versión mobile | web
© Copyright 2013, vLex. All Rights Reserved.
Contents in vLex United States
Explore vLex
For Professionals
For Partners
Company
Other interesting searches:
Concorde Capital | sherman hopkins jr | republic of moldova chisinau | Chris Hoene | Magna Pacific (Holdings) Ltd | crecimiento economico de chile | ordre du jour chsct | Erckartswiller | transporte de pasajeros de larga distancia
